Skip to main content
Retour
RPRX logo

Royalty Pharma plc

Qualité des données : 100%
RPRX
NASDAQ Healthcare Biotechnology
45,61 €
▲ 0,25 € (0,55%)
Cap. Boursière : 19,54B
Fourchette du Jour
45,05 € 46,06 €
Fourchette 52 Semaines
29,66 € 47,86 €
Volume
3 312 388
Moyenne 50J / 200J
43,70 € / 38,65 €
Clôture Précédente
45,36 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 25,4 0,4
P/B 3,0 2,9
ROE % 11,5 3,8
Net Margin % 32,4 3,9
Rev Growth 5Y % 1,0 10,0
D/E 1,4 0,2

Objectif de Cours des Analystes

Hold
49,40 € +8.3%
Low: 42,00 € High: 61,00 €
P/E Prévisionnel
9,4
BPA Prévisionnel
4,86 €
Croissance BPA (est.)
+0,0%
CA Est.
3,3 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 7,71 €
7,54 € – 7,88 €
5 B 1
FY2029 7,04 €
6,89 € – 7,19 €
4,6 B 1
FY2028 6,08 €
5,95 € – 6,22 €
4 B 1

Points Clés

Revenue grew 0,96% annually over 5 years — modest growth
Earnings declined -10,25% over the past year
ROE of 11,49% — decent returns on equity
Net margin of 32,42% shows strong profitability
Generating 2,49B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 4,10%

Croissance

Revenue Growth (5Y)
0,96%
Revenue (1Y)5,06%
Earnings (1Y)-10,25%
FCF Growth (3Y)-8,71%

Qualité

Return on Equity
11,49%
ROIC7,58%
Net Margin32,42%
Op. Margin65,58%

Sécurité

Debt / Equity
1,38
Current Ratio0,97
Interest Coverage5,07

Valorisation

P/E Ratio
25,35
P/B Ratio3,02
EV/EBITDA17,87
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5,06% Revenue Growth (3Y) 0,50%
Earnings Growth (1Y) -10,25% Earnings Growth (3Y) -17,58%
Revenue Growth (5Y) 0,96% Earnings Growth (5Y) 5,61%
Profitability
Revenue (TTM) 2,38B Net Income (TTM) 770,95M
ROE 11,49% ROA 3,93%
Gross Margin 100,00% Operating Margin 65,58%
Net Margin 32,42% Free Cash Flow (TTM) 2,49B
ROIC 7,58% FCF Growth (3Y) -8,71%
Safety
Debt / Equity 1,38 Current Ratio 0,97
Interest Coverage 5,07 Dividend Yield 0,02%
Valuation
P/E Ratio 25,35 P/B Ratio 3,02
P/S Ratio 8,22 PEG Ratio 1,04
EV/EBITDA 17,87 Dividend Yield 0,02%
Market Cap 19,54B Enterprise Value 27,87B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,38B 2,26B 2,35B 2,24B 2,29B
Net Income 770,95M 858,98M 1,13B 42,83M 619,73M
EPS (Diluted) 1,80 1,45 2,53 0,10 1,49
Gross Profit 2,38B 2,26B 2,35B 2,24B 2,29B
Operating Income 1,56B 1,29B 1,49B 307,07M 1,43B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19,62B 18,22B 16,38B 16,81B 17,52B
Total Liabilities 9,91B 7,88B 6,30B 7,29B 7,27B
Shareholders' Equity 6,48B 6,95B 6,53B 5,63B 5,78B
Total Debt 8,95B 7,61B 6,14B 7,12B 7,10B
Cash & Equivalents 618,70M 929,03M 477,01M 1,71B 1,54B
Current Assets 619,00M 1,80B 1,27B 2,55B 2,88B
Current Liabilities 636,21M 1,25B 161,38M 1,17B 171,25M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#346 of 1024
53

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026